Rapid changes in environmental conditions, increase in air and noise pollution levels, rise in geriatric population, surge in the prevalence of sinusitis and chronic rhinitis, rise in healthcare expenditure, and increase in government initiatives in developing countries fuel the growth of the global ENT disorder treatment market. However, high cost of medical devices and surgeries for sinusitis and tonsillitis hinder the market growth. On the other hand, emerging healthcare market in developing countries present new opportunities in the market in the coming years.
The global ENT disorder treatment industry generated $2.4 billion in 2021, and is estimated to reach $4.5 billion by 2031, witnessing a CAGR of 6.5% from 2022 to 2031.
The antibiotics drugs segment to lead the trail during the forecast period
Based on drug type, the antibiotics drugs segment contributed to the largest share of more than half of the global ENT disorder treatment market in 2021, and is expected to rule the roost during the forecast period. Moreover, the same segment is projected to witness the fastest CAGR of 6.9% from 2022 to 2031. This is attributed to the rise in number of ENT diseases due to increase in air and noise pollution levels as well as bacterial concentration in the environment.
The hospitals and clinics segment to maintain its dominance during the forecast period
Based on end user, the hospitals and clinics segment held the largest share of more than two-fifths of the global ENT disorder treatment market in 2021, and is likely to maintain a noteworthy growth during the forecast period. Moreover, the same segment is likely to exhibit the highest CAGR of 7.4% in 2031. The increase in the prevalence of infectious and allergic disorders such as sinusitis, tonsillitis, ear infection, nasal airway obstruction, and growing number of ENT patients visiting hospitals propel the growth of the segment.
North America to dominate in terms of revenue by 2031
Based on region, North America held the largest market share in 2021, accounting for around two-fifths of the global ENT disorder treatment market, and is likely to lead the trail throughout the forecast period. This is attributed to the increase in demand for antibiotics to treat allergic conditions like sinusitis, tonsillitis, cholesteatoma, and ear infections, and the rise in R&D facilities for the approval and development of novel antibiotic therapies in the region. However, Asia-Pacific is anticipated to manifest the fastest CAGR of 7.5% during the forecast period, 2022–2031, owing to the rise in pollution levels and surge in prevalence of infectious and allergic conditions in emerging countries like China, India, and Japan in the region.
The report analyzes these key players of the global ENT disorder treatment market. These players have adopted various strategies such as expansion, new product launches, partnerships and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.
0 Comments